News Releases

Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Researchers from the University of Pennsylvania’s Abramson Cancer Center administered CAR T cells to patients following chemotherapy, with 64 percent of patients responding in a clinical trial.

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin’s lymphoma patients.

Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD, executive director of the Basser Center for BRCA at Penn’s Abramson Cancer Center, presents new results from the Mediola and OlympiAD trials showing continued success of treating BRCA-related metastatic breast cancer with the PARP inhibitor olaparib with limited side effects for patients.

Experts from the Perelman School of Medicine at University of Pennsylvania will be presenting data on the latest advances in breast cancer research and treatment at the 2017 San Antonio Breast Cancer Symposium from December 5th through December 9th in San Antonio, TX.

Screening for tumor cells in the fallopian tubes of women at high-risk for ovarian cancer may help detect the cancer years before it develops further, suggests a new study co-led by researchers at Penn Medicine and published online this week in Nature Communications.